These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24883145)

  • 21. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic Review of Efficacy, Pharmacokinetics, and Administration of Intraventricular Aminoglycosides in Adults.
    LeBras M; Chow I; Mabasa VH; Ensom MH
    Neurocrit Care; 2016 Dec; 25(3):492-507. PubMed ID: 27043949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal aminoglycoside therapy following the sepsis: how much is too much?
    Mahmoudi L; Niknam R; Mousavi S; Ahmadi A; Honarmand H; Ziaie S; Mojtahedzadeh M
    Iran J Pharm Res; 2013; 12(2):261-9. PubMed ID: 24250599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-dose pharmacokinetics of aminoglycosides in critically ill haematological malignancy patients.
    Blackburn LM; Tverdek FP; Hernandez M; Bruno JJ
    Int J Antimicrob Agents; 2015 Jan; 45(1):46-53. PubMed ID: 25455848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Uncertainty in Antibiotic Dosing in Critically Ill Neonate and Pediatric Patients: Can Microsampling Provide the Answers?
    Dorofaeff T; Bandini RM; Lipman J; Ballot DE; Roberts JA; Parker SL
    Clin Ther; 2016 Sep; 38(9):1961-75. PubMed ID: 27544661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Amikacin Pharmacokinetics in Critically Ill Patients with Intra-abdominal Sepsis.
    Shahrami B; Najmeddin F; Rouini MR; Najafi A; Sadeghi K; Amini S; Khezrnia SS; Sharifnia HR; Mojtahedzadeh M
    Adv Pharm Bull; 2020 Jan; 10(1):114-118. PubMed ID: 32002369
    [No Abstract]   [Full Text] [Related]  

  • 28. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
    Boyer A; Gruson D; Bouchet S; Clouzeau B; Hoang-Nam B; Vargas F; Gilles H; Molimard M; Rogues AM; Moore N
    Drug Saf; 2013 Apr; 36(4):217-30. PubMed ID: 23508544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.
    Bland CM; Pai MP; Lodise TP
    Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How to measure pharmacokinetics in critically ill patients?
    Liu X; Kruger PS; Roberts MS
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2037-43. PubMed ID: 21554213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics, toxicity and cost effectiveness analysis of aminoglycosides and aminoglycoside dosing services.
    Mathews A; Bailie GR
    J Clin Pharm Ther; 1987 Oct; 12(5):273-91. PubMed ID: 3119606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.
    Alobaid AS; Hites M; Lipman J; Taccone FS; Roberts JA
    Int J Antimicrob Agents; 2016 Apr; 47(4):259-68. PubMed ID: 26988339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.
    Plaut ME; Schentag JJ; Jusko WJ
    J Med; 1979; 10(4):257-66. PubMed ID: 294466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients.
    Kovačević T; Avram S; Milaković D; Špirić N; Kovačević P
    J Basic Clin Pharm; 2016 Jun; 7(3):65-9. PubMed ID: 27330257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients.
    Hickling KG; Begg EJ; Perry RE; Atkinson HC; Sharman JR
    Crit Care Med; 1991 Aug; 19(8):1041-7. PubMed ID: 1860329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation.
    Peris-Marti JF; Borras-Blasco J; Rosique-Robles JD; Gonzalez-Delgado M
    J Clin Pharm Ther; 2004 Feb; 29(1):65-70. PubMed ID: 14748900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients.
    Schentag JJ; Cerra FB; Plaut ME
    Antimicrob Agents Chemother; 1982 May; 21(5):721-6. PubMed ID: 7103453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External Validation of Obese/Critically Ill Vancomycin Population Pharmacokinetic Models in Critically Ill Patients Who Are Obese.
    Alsultan A; Dasuqi SA; Almohaizeie A; Aljutayli A; Aljamaan F; Omran RA; Alolayan A; Hamad MA; Alotaibi H; Altamimi S; Alghanem SS
    J Clin Pharmacol; 2024 Mar; 64(3):353-361. PubMed ID: 37862131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update.
    Meng L; Mui E; Ha DR; Stave C; Deresinski SC; Holubar M
    Pharmacotherapy; 2023 Mar; 43(3):226-246. PubMed ID: 36703246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.